(Q42998971)

12 November 2017

title

Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation (English)

1 reference

12 November 2017

0 references

liver transplantation

1 reference

1 reference

M Heydtmann

1

1 reference

12 November 2017

D Freshwater

2

1 reference

12 November 2017

T Dudley

3

1 reference

12 November 2017

V Lai

4

1 reference

12 November 2017

S Palmer

5

1 reference

12 November 2017

S Hübscher

6

1 reference

12 November 2017

D Mutimer

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

American Journal of Transplantation

12 November 2017

published in

1 reference

12 November 2017

volume

6

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

825-833

1 reference

Hepatitis C virus infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Liver transplantation and hepatitis C virus: systematic review of antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Hepatitis B and hepatitis C viruses in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Treatment of hepatitis C virus infection in the allograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Hepatitis C, interferon, and risk of rejection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01255.X

10.1111/J.1600-6143.2006.01255.X

21 January 2018

Identifiers

DOI

1 reference

release_xk37nmbccrbehairb6h6zn2lbi

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xk37nmbccrbehairb6h6zn2lbi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference